Bionomics Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BNOEF research report →
About the company
Bionomics Limited, an Australian clinical-stage biopharmaceutical company founded in 1996 and based in Eastwood, focuses on identifying and developing innovative drug candidates to address central nervous system conditions and various cancers. A significant experimental medicine in their pipeline is BNC210, a negative allosteric modulator targeting the a7 nicotinic acetylcholine receptor. This compound is currently undergoing a Phase 2 clinical trial for social anxiety disorder and a Phase 2b study for post-traumatic stress disorder (PTSD).
- CEO
- Spyridon Papapetropoulos
- IPO
- 2014
- HQ
- Eastwood, SA, AU
Price Chart
- Market Cap
- $8.81M
- P/E
- -0.31
- P/S
- -1.74
- P/B
- 0.62
- EV/EBITDA
- 0.05
- Div Yield
- 0.00%
- Gross Margin
- 104.75%
- Op Margin
- 250.04%
- Net Margin
- 263.11%
- ROE
- -109.66%
- ROIC
- -77.73%
- Revenue
- $0 · -100.00%
- Net Income
- $-15,492,166,000 · -72936.61%
- EPS
- $-0.01 · 99.72%
- Op Income
- $-17,892,376,000
- FCF YoY
- -3.27%
- 52W High
- $0.06
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.02
- Beta
- 1.84
- Avg Volume
- 91.84K
Get TickerSpark's AI analysis on BNOEF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our BNOEF coverage
Recent articles, reports, and earnings notes.
No research on BNOEF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BNOEF report →Similar companies
Peers in the same neighborhood.